Beyond the Green Light: Evaluating the Uncertainties of Resmetirom for Non‐Cirrhotic Nonalcoholic Steatohepatitis Treatment

Documenti analoghi

• A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
  di: Abdul Haseeb Hasan, et al.
  Pubblicazione: (2025)
• Comparison of ABO Blood Group, Rh Factor, and Genotype Frequency Among University Students in Liberia and Pakistan: A Cross‐Sectional Study
  di: Augustine S. Samorlu, et al.
  Pubblicazione: (2026)
• Beyond Universal Healthcare: Addressing the Intricacies of Insurance Reform in Bangladesh
  di: Syed Masudur Rahman Dewan
  Pubblicazione: (2025)
• Impact of Change, Fluctuation, or Variability in Weight on the Risk of Nonalcoholic Fatty Liver Disease in General Population: A Systematic Review and Meta‐Analysis
  di: Dorsa Alijanzadeh, et al.
  Pubblicazione: (2025)
• Perturbation of Circulating Inflammatory Proteins Mediates the Relationship Between Cholecystectomy and Nonalcoholic Fatty Liver Disease: A Multivariate and Mediation Mendelian Randomization Study
  di: Cong Chen, et al.
  Pubblicazione: (2025)